ADVERTISEMENT
ADVERTISEMENT

New Products, Findings Breathe Life Into Asthma Market As Companies Expand Drug Development Opportunities

Sidebar : Asthma Products - Delivering the Dosage Asthma Products - More Information CHEMICAL BLOCKER: Accolate was the first new asthma drug approved by FDA since the 1970s. New research is breathing life into the asthma drug market. Inspired by improving knowledge of asthma's biochemistry, more than 40 companies worldwide are investigating drugs to control the disease. This effort translates into new opportunities for creative chemists and biologists. For 25 years, a handful of drug firms,

Kathryn Brown

Sidebar : Asthma Products - Delivering the Dosage
Asthma Products - More Information


CHEMICAL BLOCKER: Accolate was the first new asthma drug approved by FDA since the 1970s.
New research is breathing life into the asthma drug market. Inspired by improving knowledge of asthma's biochemistry, more than 40 companies worldwide are investigating drugs to control the disease. This effort translates into new opportunities for creative chemists and biologists.

For 25 years, a handful of drug firms, like Rhône-Poulenc Rorer and Schering Plough, have dominated the asthma market. But in the past decade, a growing number of biotech and drug companies have entered the fray. Last fall, the United States Food and Drug Administration (FDA) approved the first entirely new asthma drug since the 1970s. Called Accolate (generic: zafirlukast), the drug blocks leukotrienes, chemicals in the lungs that contribute to asthma attacks. Accolate is produced by Wilmington, Del.-based Zeneca Pharmaceuticals, a...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT